Drug interactions between Provigil and sorafenib
| Results for the following 2 drugs: |
|---|
| Provigil (modafinil) |
| sorafenib |
Interactions between your selected drugs
modafinil ↔ sorafenib
Applies to:Provigil (modafinil) and sorafenib
GENERALLY AVOID: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of sorafenib, which has been shown in vitro to be a substrate of the isoenzyme. Pretreatment with the potent inducer rifampin for 5 days prior to a single dose of sorafenib has been reported to decrease sorafenib systemic exposure (AUC) by an average of 37%. Data are not available for sorafenib in combination with other CYP450 3A4 inducers.
MANAGEMENT: The use of sorafenib in combination with potent CYP450 3A4 inducers such as carbamazepine, dexamethasone, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. Although not studied, a dosage increase of sorafenib may be considered if there are no alternatives and concomitant use with these agents is necessary. Close monitoring for sorafenib toxicity (e.g., cutaneous reactions, hemorrhage, peripheral neuropathy) is recommended if the dosage is increased. The dosage should be returned to the normally recommended dosage following discontinuation of the potent CYP450 3A4 inducer. Other known inducers include aminoglutethimide, barbiturates, bexarotene, bosentan, efavirenz, etravirine, nevirapine, and various other anticonvulsants, although the extent to which they interact with sorafenib is unknown.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
